Navigation Links
Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
Date:5/25/2011

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Gerald Wroblewski as the company's chief operations officer.  Mr. Wroblewski brings the company broad operational expertise in the areas of manufacturing, product supply chain management, packaging and quality assurance.  At Otonomy, he will be responsible for overseeing activities in these areas to support the advancement of the company's product candidates through clinical development and into commercialization.  The company recently announced plans to initiate a Phase 2 study for its lead drug candidate, OTO-104, in patients with Meniere's disease and is also positioned to begin clinical trials of a second product candidate, OTO-201, by the end of 2011.

Prior to joining Otonomy, Mr. Wroblewski served as vice president of operations at MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions.  In this role, he managed manufacturing and product supply chain activities to support clinical advancement of the company's sustained release, injectable drug candidate.  Before his work with MacuSight, he was chief operating officer at iScience Interventional Inc., a start-up medical device company in the ophthalmology space, and executive vice president of operations at Oculex Pharmaceuticals, a developer of novel biodegradable therapeutics for diseases of the eye.  While at Oculex, Mr. Wroblewski was responsible for developing and implementing GMP manufacturing systems designed to support the production of multiple product components related to the company's sustained release steroid formulation.  These innovative manufacturing platforms supported the advancement of the product into late-stage clinical trials and ultimately contributed to Allergan's successful acquisition of Oculex for $230 million.  During his career, Mr. Wroblewski has also held senior management positions in large-scale commercial manufacturing operations at The Gillette Company, Oral-B Laboratories and McGaw Laboratories.  

"The positive clinical results we recently announced for OTO-104 in Meniere's disease, combined with our rapid progress advancing OTO-201 through IND enabling studies, signals an important transition for the company that requires additional operational expertise and focus," said David A. Weber, Ph.D., president and chief executive officer of Otonomy.  "I welcome the opportunity to work with Jerry again and know that his depth and breadth of manufacturing expertise will successfully support the company through clinical development. Furthermore, his experience in commercial manufacturing operations will be essential to achieving our long range business objectives of bringing our products to market."  

About OtonomyOtonomy is a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear.  There are currently no FDA-approved drug treatments for the nearly 30 million Americans that are affected by debilitating hearing and balance diseases and disorders such as Meniere's disease, sudden sensorineural hearing loss, noise-induced hearing loss, age-related hearing impairment and tinnitus.  Otonomy's core technology is a sustained release formulation developed for optimal delivery of drugs to the middle and inner ear with a single intratympanic (IT) injection.  This technology has broad applicability across a range of therapeutic classes and two products based on this platform are in active development.

Otonomy's lead product candidate, OTO-104, is a sustained release formulation of the steroid dexamethasone.  A Phase 1b clinical trial in Meniere's disease patients has recently been completed, and future studies are being planned in Meniere's disease and other inner ear disorders.  OTO-201, the company's second product candidate, is a novel sustained release antibiotic being developed for the treatment of chronic otitis media.  OTO-201 clinical trials are expected to begin in 2011.  Additional product candidates are expected to target acute and chronic forms of hearing loss, balance disorders, and tinnitus.

For more information visit: www.otonomy.com.Contact:Vida Communication (On behalf of Otonomy)Stephanie Diaz (investors)

Tim Brons (media)415-675-7400

415-675-7400sdiaz@vidacommunication.com

tbrons@vidacommunication.com
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
2. Otonomy Introduces Scientific Advisory Board
3. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
4. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
5. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
6. BioStorage Technologies Appoints New Director of Business Development for European Operations
7. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
8. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
9. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
10. Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality
11. OncoSec Medical Appoints Punit Dhillon as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... 2016 AskLinkerReports.com has published a report ... Amyloglucosidase Industry 2016 Market Research Report. From a basic outline ... overview are all covered in the report. This report projects ... analysis of the Amyloglucosidase industry. ... , , ...
(Date:12/8/2016)... , Dec. 8, 2016  Renova™ Therapeutics, ... congestive heart failure and type 2 diabetes, announced ... a novel adeno-associated virus (AAV) vector developed in ... M.D., Ph.D., at Stanford University. The company plans ... paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... CARDIFF, UK (PRWEB) , ... December 08, 2016 ... ... high precision light to control cells — optogenetics — is key to exciting ... state of the art, spatially patterned light projected via free-space optics stimulates small, ...
(Date:12/8/2016)... 2016 Oxford Gene ... seine Palette an anpassbaren SureSeq™ NGS-Panels mit dem ... das ein schnelles und kostengünstiges Studium der Varianten ... eine Erkennung von Einzel-Nukleotid-Variationen (Single Nucleotide Variation, SNV) ... kleinen Panel und ermöglicht eine individuelle Anpassung durch ...
Breaking Biology Technology:
(Date:12/7/2016)... Dec. 7, 2016   Veridium , a ... appointment of new CEO James Stickland . ... decades of experience, has served in senior executive ... he specialized in expanding a pipeline of venture ... He most recently served as managing director of ...
(Date:12/6/2016)... Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, and the Prison ... (5) year funding commitment by Securus to PEP ... and reentry support to more inmates and their ... the Prison Entrepreneurship Program (PEP) is an independent ...
(Date:12/2/2016)...   SoftServe , a global digital technology ... electrocardiogram (ECG) biosensor analysis system for continuous driver ... The smart system ensures device-to-device communication between ECG ... mobile devices to easily ,recognize, and monitor users ... technology advances, so too must the security systems ...
Breaking Biology News(10 mins):